You’re using a public version of DrugChatter with 1 free searches available. Register to unlock more free searches per day. CREATE FREE ACCOUNT

Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

When will a generic vascepa be released?



Vascepa is a prescription medication used to treat high triglyceride levels in the blood. The active ingredient in Vascepa is eicosapentaenoic acid (EPA). According to the sources provided, a generic version of Vascepa is expected to be released soon.

The first source [1] indicates that the patent for Vascepa expired in September 2020. However, Amarin, the manufacturer of Vascepa, has been fighting to protect its patent through litigation. The second source [2] confirms that Amarin lost its patent appeal in March 2021, which means that a generic version of Vascepa could be released soon.

The third source [3] reports that Prime Therapeutics, a pharmacy benefit manager, has removed Vascepa from its Medicare formularies as of July 1, 2021. This suggests that a generic version of Vascepa may be available soon, as Prime Therapeutics typically removes brand-name drugs from its formularies once a generic version becomes available.

In conclusion, while there is no exact release date for a generic version of Vascepa, the expiration of the patent and the loss of Amarin's patent appeal suggest that it could be released soon. The removal of Vascepa from Prime Therapeutics' Medicare formularies also indicates that a generic version may be available in the near future.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/VASCEPA
[2] https://www.fiercepharma.com/marketing/it-s-confirmed-amarin-loses-patent-appeal-protecting-blockbuster-hopeful-vascepa-from
[3] https://www.formularywatch.com/view/prime-therapeutics-two-drugs-from-medicare-formularies



Follow-up:   What is the cost of Vascepa compared to generics? Are there any side effects of Vascepa? How effective is Vascepa in reducing cardiovascular risk?





DrugPatentWatch - Make Better Decisions
© thinkBiotech LLC 2004 - 2024. All rights reserved.